EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts

Hui Huang, Qian Wang, Zuojun Xu iD

Therapeutic Advances in Respiratory Disease · 2024

DOI: 10.1177/17534666241288417 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2024. Verfasst von Hui Huang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical…. Hauptthemen laut MEDLINE: Disease Progression, Pulmonary Fibrosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibrosing interstitial lung diseases (FILDs) other than idiopathic pulmonary fibrosis (IPF) can develop into progressive pulmonary fibrosis (PPF) despite initial management. A substantial proportion of patients with non-IPF interstitial lung diseases (ILDs) progress to PPF, including connective tissue disease-associated ILD (such as rheumatoid arthritis-associated ILD, systemic sclerosis-associated ILD, and idiopathic inflammatory myositis-associated ILD), fibrosing hypersensitivity pneumonitis, and fibrosing occupational ILD. The concept of PPF emerged only recently and several studies have confirmed the impact of PPF on mortality. In addition to poor prognosis among patients with PPF, there remains a lack of consensus in the diagnosis and treatment of PPF across different types of ILDs. There is a need to raise awareness of PPF in FILDs and to explore measures to improve PPF diagnosis and treatment, which in turn could potentially reduce the progression from FILD to PPF. This review discusses the disease burden of PPF and recent advances in the management of PPF among patients with ILDs, including antifibrotic medications that have emerged as promising treatment options. Additionally, this review highlights the perspectives of expert Chinese physicians with regard to their experience in managing PPF in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disease ProgressionPulmonary FibrosisHumansAntifibrotic AgentsChinaLungLung Diseases, InterstitialTreatment Outcome

Stichwörter der Autor:innen

fibrosing hypersensitivity pneumonitisfibrosing occupational ILD; fibrosing interstitial lung diseaseidiopathic inflammatory myositisprogressive pulmonary fibrosisrheumatoid arthritissystemic sclerosis

Substanzen

Antifibrotic Agents

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan Street, Dongcheng District, Beijing 100730,…

ORCID-Profile: Zuojun Xu

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Huang, H., Wang, Q., & Xu, Z. (2024). Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666241288417

Vancouver

Huang H, Wang Q, Xu Z. Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts. Therapeutic Advances in Respiratory Disease. 2024. doi:10.1177/17534666241288417

BibTeX
@article{Huang2024,
  author = {Huang, Hui and Wang, Qian and Xu, Zuojun},
  title = {Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2024},
  doi = {10.1177/17534666241288417}
}
Kostenlos starten →